Literature DB >> 11197215

Lymphoid blast crisis during interferon-alpha therapy in a patient with chronic myelogenous leukemia in myeloid blast crisis.

H Goto1, H Tsurumi, T Hara, H Moriwaki.   

Abstract

A 47-year-old woman was admitted to the hospital on March 13, 1998, because of general malaise and fever. It was determined that she had chronic myelogenous leukemia (CML) in myeloid blast crisis. Hydroxyurea was started initially, and the blasts completely disappeared from peripheral blood on day 9 of therapy. Interferon (IFN)-alpha was subsequently started, but lymphoblasts newly appeared on day 13 of administration. Treatment with adriamycin, vincristine, and prednisolone (AdVP) was immediately started, which rapidly reduced the lymphoblasts. However, the myeloblasts again began to gradually increase. Subsequent examinations showed the combined presence of myeloblasts and lymphoblasts in the marrow and peripheral blood. The ratio between myeloblasts and lymphoblasts depended on the treatment (IFN-alpha or AdVP). The patient died from respiratory failure on November 16, 1998. This patient may have had an underlying bipotential blastic clone that evolved differently in response to IFN-alpha or AdVP. In some CML patients, IFN-alpha may induce lymphoid blast crisis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11197215

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

1.  Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.

Authors:  Akihiko Gotoh; Keisuke Miyazawa; Yoshiko Uchida; Goro Sashida; Ken Kawakubo; Yuzuru Kuriyama; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

2.  Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis.

Authors:  C Calderón-Cabrera; I Montero; R M Morales; J Sánchez; E Carrillo; T Caballero-Velázquez; C Prats; R Bernal; J M De Blas; J A Pérez-Simón
Journal:  Leuk Res Rep       Date:  2013-09-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.